Plenge Gen @rplenge

Last month, retired U.S. soccer champion Abby Wambach visited Bristol Myers Squibb for our People Week keynote event.

As a senior leader at a biopharma company, I am often asked to speak to young professionals about careers in healthcare and, specifically, my career journey.

When I think about our vision for AI and automation at Bristol Myers Squibb, I think about the music video by the band OK Go for their song “This Too Shall Pass.”

Until a few months ago, I hadn’t given much thought to Moloch, the ancient figure associated in historical texts with extreme and costly sacrifices.

Introduction I just got back from the annual J.P.

Early in my career, I was often asked, “Do you want to work in academia or industry?”

If you’ve followed this blog for a while, you’ll know I often say drug discovery is more like poker than chess (see here and here).

In a previous blog post, I argued that pharmaceutical Research and Development (R&D) is more like poker than chess given the probabilistic nature of developing new medicines.

When I last wrote about AI on this blog three years ago, I spoke of it being a tool with the potential to transform scientific discovery, but the application I described was primarily theoretical.

Last week I visited the University of Pennsylvania for a fireside chat with Roger Greenberg, a Professor in the Department of Cancer Biology, as part of the Wharton Undergraduate Healthcare Club (WUHC).